modelArtenimolAndPiperaquine
Extends from Pharmacolibrary.Drugs.ATC.P.P01BF05.
Information
| name: | ArtenimolAndPiperaquine | |
| ATC code: | P01BF05 | route: | oral |
| compartments: | 3 | |
| dosage: | 640 | mg |
| volume of distribution: | 764 | L |
| clearance: | 44 | L/h |
| other parameters in model implementation | ||
Artenimol (dihydroartemisinin) and piperaquine is a fixed-dose combination antimalarial drug indicated for the treatment of uncomplicated Plasmodium falciparum malaria. Artenimol is a semi-synthetic derivative of artemisinin and acts rapidly against malaria parasites, while piperaquine, a 4-aminoquinoline compound, provides a longer-acting effect, together lowering the risk of recrudescence. It is approved and recommended for use in many endemic regions and is included in the WHO guidelines for malaria therapy.
Pharmacokinetics
Population pharmacokinetics of piperaquine and artenimol in adults and children with uncomplicated P. falciparum malaria (including both sexes), using data from Asian and African populations. Parameters reflect standard oral dosing (3 daily doses at 0, 24, 48 h).
References
Reuter, SE, et al., & Pace, S (2015). Effect of food on the pharmacokinetics of piperaquine and dihydroartemisinin. Clinical drug investigation 35(9) 559–567. DOI:10.1007/s40261-015-0312-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26293519
Tarning, J, et al., & Lindegardh, N (2012). Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clinical pharmacology and therapeutics 91(3) 497–505. DOI:10.1038/clpt.2011.254 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22258469
Tarning, J, et al., & Lindegardh, N (2012). Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria. Antimicrobial agents and chemotherapy 56(4) 1997–2007. DOI:10.1128/AAC.05756-11 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22252822
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.Volume | Vdp (from PK_2C) | VdpPerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | VdpPerKg (from PK_2C) | 0.9 | Volume of distribution peripheral(l/kg) |
| Pharmacolibrary.Types.Clearance | k12 (from PK_2C) | 1 | intercompartmental C-P clearance |
| Pharmacolibrary.Types.Clearance | k21 (from PK_2C) | 1 | intercompartmental P-C clearance |
| Pharmacolibrary.Types.Volume | Vdp2 (from PK_3C) | Vdp2PerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | Vdp2PerKg (from PK_3C) | 0.9 | Volume of distribution peripheral 2 (l/kg) |
| Pharmacolibrary.Types.VolumeFlowRate | k13 (from PK_3C) | 1 | intercompartmental 1-3 clearance (l/min) |
| Pharmacolibrary.Types.VolumeFlowRate | k31 (from PK_3C) | 1 | intercompartmental 3-1 clearance (l/min) |
| Pharmacolibrary.Types.TransferRate | ka (from PK_3C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_3C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | peripheralCPort (from PK_2C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral1 (from PK_2C) | ||
| Interfaces.ConcentrationPort_b | perihperal2Cport (from PK_3C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral2 (from PK_3C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life | |
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral1 (from PK_3C) | ||
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer1 (from PK_3C) |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)